Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients

Boyd, Anders; Canini, Laetitia; Gozlan, Joël; Lascoux-Combe, Caroline; Miailhes, Patrick; Fonquernie, L.; Girard, Pierre‐Marie; Lacombe, Karine

doi:10.1016/j.jcv.2017.08.008

Cited by 7 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our cross-sectional and prospective studies showed that there was no relationship between rs3077 minor allele homozygote and HBV clearance; this finding corresponds to that of a previous study conducted in Taiwan (16). Although it may be roughly speculated that the irrelevance of rs3077 could be because of the www.globalhealthmedicine.com Previous study findings show that the rate of HBsAg clearance after initiation of different therapeutic strategies among HIV/HBV co-infected individuals varied between 1.7% and 2.6%/person-years; this was lower than the value of 4.9%/person-years determined in the current study (17)(18)(19). This result may be attributed to the relatively longer follow-up period in our study.…”

Section: Discussioncontrasting

confidence: 79%

Possible association of <i>HLA-DP</i> polymorphism and antiretroviral therapy with hepatitis B virus clearance in an HIV-infected Vietnamese population

Mizushima

Hayashida

Nguyen

et al. 2022

GHM

View full text Add to dashboard Cite

There is little evidence regarding the association between hepatitis B virus (HBV) chronicity and HLA-DP among the HIV-infected Vietnamese population. To study this, we conducted a cross-sectional analysis and a prospective study involving an HIV-infected Vietnamese cohort. The association between HBV chronicity and HLA-DP single nucleotide polymorphisms (SNPs) of rs3077 and rs9277535 among Vietnamese patients with previous HBV exposure was first evaluated. In addition, treatment-naive patients with chronic HBV infection were followed between 2012 and 2017 for HBV clearance after the initiation of antiretroviral therapy (ART). A total of 820 subjects with previous HBV exposure were included in the cross-sectional study. Among them, 147 (17.9 %) had chronic HBV infection, and 673 (82.1 %) achieved HBV clearance. The proportions of minor allele homozygotes of rs3077 and rs9277535 were 10.9 % and 15.2 % (p = 0.481) and 4.1 % and 11.7 % (p = 0.003), respectively. Multivariate analysis showed that rs9277535 minor homozygote was a significant protective factor against chronic HBV infection (odds ratio [OR], 0.271; 95 % confidence interval [CI]; 0.114-0.642, p = 0.001). Further, none of the 43 patients in the prospective study, who received ART possessed the rs9277535 minor homozygote. The average follow-up period was 4.8 years, and 10 subjects (23.3 %, 4.9 %/person-years) achieved HBV clearance. Univariate analysis revealed that the SNPs were not significantly associated with HBV clearance. In conclusion, our study confirmed that the rs9277535 minor allele homozygote was significantly associated with HBV clearance among HIV-infected Vietnamese patients.

show abstract

Section: Discussioncontrasting

confidence: 79%

Possible association of <i>HLA-DP</i> polymorphism and antiretroviral therapy with hepatitis B virus clearance in an HIV-infected Vietnamese population

Mizushima

Hayashida

Nguyen

et al. 2022

GHM

View full text Add to dashboard Cite

show abstract

“…Regarding the risk factors for liver fibrosis, it is expected that the cumulative exposure to ART leads to a gradual decline on the impact of various risk factors for liver fibrosis, In this respect, studies on patients undergoing ART show discordant data on various risk factors for liver fibrosis such as advancing age, male gender, detectable HIV RNA, lower CD4 T cell counts as well as the presence of HBV/HCV coinfection and detectable plasma HBV DNA (4,16,17,33,36,39). Individuals with HIV-HBV co-infection and well-controlled viral loads on prolonged ART display lower scores of liver fibrosis, comparable with the scores found in people with HIV mono-infection (36) and a lower rate of significant liverrelated complications (8,22). Nevertheless, these patients are less likely to display a regression of liver fibrosis despite the ongoing administration of ART.…”

Section: Discussionsupporting

confidence: 54%

“…HBV co-infection aggravates the course of liver disease and favors the progression to cirrhosis and the development of hepatocellular carcinoma. Following ART, the rate of HBsAg loss in HIV-HBV co-infected individuals has been shown to be higher compared with treated HBV monoinfection (7)(8)(9). Nevertheless, the HBV infection has been shown to be associated with a higer mortality in PLWH irrespective on the presence active or previous HBV replication and cases which have already developed moderate or advanced liver fibrosis are less likely to display a histologic regression of the liver injury after HBeAg or HBsAg seroclearence (10,11).…”

Section: Introductionmentioning

confidence: 99%

Liver fibrosis progression in a cohort of young HIV and HIV/ HBV co-infected patients: A longitudinal study using non-invasive APRI and Fib-4 scores

Iacob

Luminos²,

Benea³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundThe risk of liver fibrosis increases over time in HIV and HIV-HBV individuals even under antiretroviral treatment (ART), warranting a rigorous and periodic monitorization. Given the lower availability of transient elastography, we aimed to assess the longitudinal variation of two non-invasive liver fibrosis scores, APRI and Fib-4, in cases with HIV monoinfection, HIV-HBV co-infection and individuals with HBsAg-seroclearance.MethodsWe performed an observational retrospective study between 2013 and 2019 on 212 HIV patients including 111 individuals with HIV mono-infection, 62 individuals with HIV-HBV co-infection and positive HBsAg and 39 cases with HIV-HBV infection and HBsAg-loss. The groups were followed at 36, 48, and 60 months. Liver fibrosis was indicated by an APRI >0.5 or Fib-4≥1.45 score and advanced fibrosis by an APRI score >1.5 or Fib-4 >3.25. Logistic regression with generalized estimating equations (GEE) was used to assess the predictors for the presence of liver fibrosis over time.ResultsDuring a median follow-up of 58.5 months the prevalence of liver fibrosis in all patients increased with 0.5% reaching 11.3% using an APRI score and with 0.9% reaching 10.8% using the Fib-4 score. At the visit corresponding to 60 months the prevalence of liver fibrosis was higher in all HIV-HBV patients compared with individuals with HIV mono-infection, namely: 16.1% on APRI and 12.9% on the Fib-4 score in HIV-HBV/HBsAg-positive individuals, 12.8% on both APRI and Fib-4 scores in HIV-HBV/HBsAg-negative individuals vs. 8.1 and 9%, respectively in HIV mono-infection. The presence of liver fibrosis over the study period was independently associated with plasma HIV RNA, CD4+T cell counts, HIV-HBV co-infection (for APRI >0.5) and ART non-adherence (for Fib-4 >1.45). At the final visit, non-adherence to ART and CD4+T cell counts remained associated with liver fibrosis.ConclusionsThe study found a slow progression of APRI and Fib-4 scores over time in young PLWH with extensive ART. Liver fibrosis scores continued to increase in patients with HIV mono-infection yet remained lower than in HIV-HBV patients irrespective on the presence of HBsAg. The periodic follow-up using non-invasive scores on the long-term could help improve the surveillance in low-income settings and high scores should be followed by additional diagnostic methods.

show abstract

“…The median rate of treated co-infected individuals able to achieve HBsAg-seroclearance and acquire anti-hepatitis B surface (anti-HBs) antibodies, which defines “HBsAg-seroconversion,” is at 0.92 per 100 person-years [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 28 , 30 ]. In general, HBsAg-seroclearance will eventually lead to HBsAg-seroconversion in roughly half of co-infected individuals; however, anti-HBs antibodies can take years to develop and when present, are at relatively lower levels than expected after acute HBV infection in HIV-negative individuals or after HBV vaccination [ 31 ].…”

Section: Functional Cure In Hiv-hbv Co-infected Individuals Undergoing Potent Anti-hbv Therapymentioning

confidence: 99%

Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review

Boyd

Dezanet

Lacombe

2021

Viruses

Self Cite

View full text Add to dashboard Cite

In individuals infected with hepatitis B virus (HBV), the loss of hepatitis B surface antigen (HBsAg) is the ultimate therapeutic goal, which defines “functional cure.” For individuals living with human immunodeficiency virus (HIV), functional cure occurs roughly 2 per 100 person-years during potent anti-HBV containing antiretroviral therapy. Although this rate may be higher than expected in treated HBV mono-infected individuals, rates of functional cure widely vary between studies (0.6–10.5 per 100 person-years). Similar to HBV mono-infection, the phase of HBV infection, HBV (sub-)genotypes and hepatitis B “e” Ag-negative variants are associated with functional cure in treated HIV-HBV co-infection. In specifically HIV-HBV co-infected individuals, strong increases in CD4+ T cell counts after treatment initiation have also been linked to functional cure, yet this finding is inconsistent across studies. Several markers directly or indirectly reflecting HBV activity are being developed to predict functional cure, such as quantification of HBsAg, hepatitis B core-related antigen, HBsAg protein composition, anti-hepatitis B core antibodies and interferon-gamma-inducible protein 10. Few have been assessed during treatment in HIV-HBV co-infected individuals and none have been validated to predict functional cure. Novel therapeutics for HBV cure are essential for individuals with HIV-HBV co-infection and need to be separately evaluated in this population.

show abstract

Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients

Abstract: Most co-infected patients with HBsAg-seroconversion produced and maintained stable antibody levels, yet kinetics of anti-HBs production were much slower compared to those observed post-vaccination or after clearance of acute HBV-infection.

Cited by 7 publications

References 37 publications

Possible association of <i>HLA-DP</i> polymorphism and antiretroviral therapy with hepatitis B virus clearance in an HIV-infected Vietnamese population

Possible association of <i>HLA-DP</i> polymorphism and antiretroviral therapy with hepatitis B virus clearance in an HIV-infected Vietnamese population

Liver fibrosis progression in a cohort of young HIV and HIV/ HBV co-infected patients: A longitudinal study using non-invasive APRI and Fib-4 scores

Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review

Contact Info

Product

Resources

About